Opening a new era in neurology

Braintale biomarkers’ potential has been demonstrated in selected myelinopathies notably adrenoleukodytrophy (ALD).

ALD affects 30 000 patients EU and US and is a life-threatening disease where no therapeutic option is available today.

Braintale enables drug developers and clinicians to take the appropriate decision of patients’ inclusion, early diagnostic, disease monitoring and follow-up.

Braintale’s proprietary biomarkers are correlated with traditional clinical scores and can discriminate significantly between active and placebo arms.


BRAINTALE, whose head office is 11 rue de l’Académie 67000 – STRASBOURG, is registered in the Trade and Companies Register under number 840 995 138 RCS STRASBOURG 

Last update : 09/19/2022